Tag: Humacyte

Humacyte commences phase II vascular trauma trial

Humacyte has announced the initiation of a US phase II vascular trauma clinical trial of Humacyl, its investigational human acellular vessel, for vascular replacement...

Humacyte appoints Doug Blankenship as chief financial officer

Humacyte has announced the appointment of Douglas L Blankenship as chief financial officer, effective Monday, 8 October, 2018. According to a company release, Blankenship is...

Humacyte appoints Jeffrey Lawson as president and CEO

Humacyte, an innovator in biotechnology and regenerative medicine, has announced that Jeffrey Lawson has been appointed president and chief executive officer. The former chairman...

Fresenius and Humacyte enter strategic global partnership with US$150M equity investment

Fresenius Medical Care, the world's largest provider of dialysis products and services, and Humacyte, Inc., a medical research, discovery and development company, have announced...

Humacyte’s Humacyl receives US FDA expedited review designation

The US Food and Drug Administration (FDA) has granted Humacyte’s Humacyl investigational human acellular vessel (HAV) Regenerative Medicine Advanced Therapy (RMAT) designation. This designation means...

Humacyte commences US phase II arterial bypass clinical trial

Humacyte has announced the initiation of a US phase II arterial bypass clinical trial of Humacyl, an investigational human acellular vessel, to test its safety...